Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Phase 1 Study of Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody in Solid Tumors

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Baxalta US Inc.
ClinicalTrials.gov Identifier:
NCT01765790
First received: January 9, 2013
Last updated: September 13, 2016
Last verified: September 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: July 2016
  Primary Completion Date: July 2016 (Final data collection date for primary outcome measure)